68Ga-FAPI, Ovarian Cancer, Epithelial Ovarian Cancer, Positron Emission Tomography
Conditions
Keywords
68Ga-FAPI, PET, ovarian cancer, recurrence detection
Brief summary
This is a prospective study to investigate the potential efficacy of 68Ga-FAPI PET/CT for recurrence detection of epithelial ovarian cancer in comparison with 18F-FDG PET/CT.
Detailed description
Gallium 68-labeled fibroblast-activation protein inhibitor (68Ga-FAPI) has recently been a potential radiotracer for gynecological malignancies,including ovarian cancer. Early detection and localization of sites of recurrence helps to identify ovarian cancer patients who will benefit the most from secondary surgery, chemotherapy, or radiation therapy. Its clinical utility for recurrence detection of epithelial ovarian cancer and histological validation of FAPI findings is not well established.
Interventions
DIAGNOSTIC_TEST68Ga-FAPI
\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
Sponsors
RenJi Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Inclusion criteria
* adult patients (age\>18 and\<80 years) * patients with clinically suspected recurrent ovarian cancer * patients who underwent paired 18F-FDG and 68Ga-FAPI PET/CT for the most proper treatment strategy within 1 week * patients who did not receive any other treatment 4 weeks before PET imaging
Exclusion criteria
* pregnant patients * patients with poor performance status * patients unwilling to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Performance | 1 year | Sensitivity and Specificity of 68Ga-FAPI PET/CT for recurrence in comparison with 18F-FDG PET/CT |
| Maximum standardized uptake value（SUVmax） | 1 year | Measurement of the maximum standardized uptake value of the lesion |
| Tumor-to-background ratio (TBR) | 1 year | TBR was calculated according to the formula：TBR=SUVmax of lesion/SUVmax of background |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between FAPI expression and SUV in PET | 1 year | Correlation between 68Ga-FAPI PET uptake intensity and histopathologic FAP expression. Validation via immunohistochemical FAP staining of pathological specimen |
Countries
China
Contacts
Primary ContactTingting Wang, PH.D
Outcome results
None listed